Assessing the impact of protocol design changes on clinical trial performance

DOI: 10.1097/mjt.0b013e31816b9027
American Journal of Therapeutics, 2008, 15, 450-7.

#	Paper	IF	Citations
111	Clinical trial participation: are we studying the patients we are trying to treat?. **2009**, 11, 1021-2		8
110	Clinical research sites--the underappreciated component of the clinical research system. **2009**, 302, 2025-7		28
109	Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. **2009**, 151, 206-9		230
108	Considerations for hospital approval of human participant research. **2010**, 5, E17-24		
107	Deconstructing the drug development process: the new face of innovation. **2010**, 87, 356-61		241
106	Trends in risks associated with new drug development: success rates for investigational drugs. **2010**, 87, 272-7		563
105	Bridging the gap: improving clinical development and the regulatory pathways for health products for neglected diseases. **2010**, 7, 719-34		23
104	Why do we pay? A national survey of investigators and IRB chairpersons. **2010**, 5, 43-56		31
103	A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). **2010**, 62, 896-918		63
102	Relation of study design to recruitment and retention in CTN trials. **2011**, 37, 426-33		8
101	Variability in Protocol Design Complexity by Phase and Therapeutic Area. **2011**, 45, 413-420		19
100	View and present status of personnel involved in clinical trials: a survey of participants from the First Symposium of the Shikoku Collaborative Group for Promotion of Clinical Trials. **2011**, 58, 81-5		3
99	A National Cancer Clinical Trials Network: recommendations from the Institute of Medicine. *American Journal of Therapeutics*, **2011**, 18, 382-91	1	24
98	Open mind, open collaboration. **2011**, 5, 701-3		
97	Death of the Blockbuster and Pivotal Clinical Trial: Rethinking the Drug Development Process. **2011**, 41, 94-96		
96	Ontario protocol assessment level: clinical trial complexity rating tool for workload planning in oncology clinical trials. **2011**, 7, 80-4		17
95	Impediments to clinical research in the United States. **2012**, 91, 535-41		35

94	Capturing patients' perspectives of treatment in clinical trials/drug development. **2012**, 33, 23-8		12
93	Distance from home to study clinic and risk of follow-up interruption in a cohort of HIV-1-discordant couples in Nairobi, Kenya. **2012**, 7, e43138		10
92	R&D Costs and Returns to New Drug Development: A Review of the Evidence. **2012**,		8
91	Clinical Trial Implementation, Analysis, and Reporting:. 338-351		
90	Clinical trials management at the site level. 148-155		
89	Clinical Trial Planning:. 309-337		
88	2-Azabicyclo[2.2.1]hept-5-en-3-one: chemical profile of a versatile synthetic building block and its impact on the development of therapeutics. **2012**, 112, 4642-86		95
87	Rescuing clinical trials in the United States and beyond: a call for action. **2013**, 165, 837-47		40
86	Integration of patient-reported outcomes in multiregional confirmatory clinical trials. **2013**, 35, 62-9		16
85	Upholding the principles of autonomy, beneficence, and justice in phase I clinical trials. **2013**, 18, 242-4		6
84	Measuring clinical trial-associated workload in a community clinical oncology program. **2013**, 9, 211-5		15
83	Factors Related to Regulatory Approval of Late-Stage Development Compounds: Analysis of Japanese Pharmaceutical Company Activities, 1995-2007. *Therapeutic Innovation and Regulatory Science*, **2013**, 47, 261-267	1.2	1
82	Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies. **2013**, 8, e71966		18
81	Improving protocol design feasibility to drive drug development economics and performance. **2014** , 11, 5069-80		27
80	Developments in Statistical Evaluation of Clinical Trials. **2014**,		1
79	Pharmaceutical new product development: why do clinical trials fail?. **2014**, 44, 189-202		10
78	Clinical trials in crisis: Four simple methodologic fixes. **2014**, 11, 615-21		36
77	Five-step authorship framework to improve transparency in disclosing contributors to industry-sponsored clinical trial publications. **2014**, 12, 197		26

76	Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials. **2014**, 11, 553-9		5
75	Patient enrollment onto clinical trials: the role of physician knowledge. **2014**, 29, 74-9		2
74	U.S. Food and Drug Administration inspections of clinical investigators: overview of results from 1977 to 2009. **2014**, 20, 3364-70		10
73	'Project launch': from research finding to therapeutic product. **2014**, 51, 123-36		3
72	The need for harmonized structured documentation and chances of secondary use - results of a systematic analysis with automated form comparison for prostate and breast cancer. **2014**, 51, 86-99		18
71	Increasing value and reducing waste in biomedical research regulation and management. **2014**, 383, 176-85		281
70	Accrual and recruitment practices at Clinical and Translational Science Award (CTSA) institutions: a call for expectations, expertise, and evaluation. **2014**, 89, 1180-9		15
69	Financial returns on R&D: looking back at history, looking forward to adaptive licensing. **2015**, 10, 28-43		6
68	User Satisfaction Evaluation of the EHR4CR Query Builder: A Multisite Patient Count Cohort System. **2015**, 2015, 801436		5
67	Frequency analysis of medical concepts in clinical trials and their coverage in MeSH and SNOMED-CT. **2015**, 54, 83-92		16
66	Efficiency and effectiveness evaluation of an automated multi-country patient count cohort system. **2015**, 15, 44		4
65	Accrual Index: A Real-Time Measure of the Timeliness of Clinical Study Enrollment. **2015**, 8, 655-61		4
64	Site selection for heart failure clinical trials in the USA. **2015**, 20, 375-83		9
63	The Impact of Bad Protocols. **2015**, 105-116		1
62	Re-Engineering Clinical Trials. **2015**, 41-53		
61	Quantifying the magnitude and cost of collecting extraneous protocol data. *American Journal of Therapeutics*, **2015**, 22, 117-24	1	19
60	Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats. **2015**, 56, 1793-9		8
59	Testing the Ability of Selenium and Vitamin E to Prevent Prostate Cancer in a Large Randomized Phase III Clinical Trial. **2016**, 567-582		1

58	Public- and Private-Sector Contributions to the Research and Development of the Most Transformational Drugs in the Past 25 Years: From Theory to Therapy. *Therapeutic Innovation and Regulatory Science*, **2016**, 50, 759-768	1.2	26
57	Optimization of protocol design: a path to efficient, lower cost clinical trial execution. **2016**, 2, FSO89		3
56	Activating clinical trials: a process improvement approach. **2016**, 17, 106		6
55	Process Innovation Improves Trial Operation Efficiency. *Therapeutic Innovation and Regulatory Science*, **2016**, 50, 510-514	1.2	
54	Applying Comparative Effectiveness Data to Medical Decision Making. **2016**,		
53	Key cost drivers of pharmaceutical clinical trials in the United States. **2016**, 13, 117-26		177
52	Innovation in the pharmaceutical industry: New estimates of R&D costs. **2016**, 47, 20-33		1486
51	Randomized Controlled Trials. **2016**, 13-25		2
50	Cost-benefit assessment of using electronic health records data for clinical research versus current practices: Contribution of the Electronic Health Records for Clinical Research (EHR4CR) European Project. **2016**, 46, 85-91		29
49	Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany. *Therapeutic Innovation and Regulatory Science*, **2016**, 50, 221-227	1.2	11
48	Factors That Affect the Acquisition of Reward Premiums for Promotion of Innovative Drug Discovery in Japan. *Therapeutic Innovation and Regulatory Science*, **2016**, 50, 56-65	1.2	16
47	Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic Area. *Therapeutic Innovation and Regulatory Science*, **2016**, 50, 49-55	1.2	14
46	The Learning Healthcare System and Cardiovascular Care: A Scientific Statement From the American Heart Association. **2017**, 135, e826-e857		54
45	How many research nurses for how many clinical trials in an oncology setting? Definition of the Nursing Time Required by Clinical Trial-Assessment Tool (NTRCT-AT). **2017**, 23, e12497		4
44	A Randomized Controlled Trial of an Additional Funding Intervention to Improve Clinical Trial Enrollment. **2017**, 15, 1104-1110		2
43	Intra-Target Microdosing - A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans. **2017**, 10, 351-359		4
42	The Burden of the "False-Negatives" in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures. **2017**, 10, 470-479		10
41	Clinical trials from the patient perspective: survey in an online patient community. **2017**, 17, 166		40

40	Increasing protocol suitability for clinical trials in sub-Saharan Africa: a mixed methods study. **2017**, 2, 11		2
39	Agreement in reporting between trial publications and current clinical trial registry in high impact journals: A methodological review. **2018**, 65, 144-150		9
38	Clinical Trial Design for Myasthenia Gravis. **2018**, 335-344		
37	New Benchmarks Characterizing Growth in Protocol Design Complexity. *Therapeutic Innovation and Regulatory Science*, **2018**, 52, 22-28	1.2	16
36	The pharmaceutical market and drug development prognosis in Japan: Current and future perspectives according to pharmacological classes. **2018**, 14, 70-80		4
35	The risk of innovation: measuring drug clinical development in Brazil. **2018**, 17, 128		1
34	Assessing Patient Participation Burden Based on Protocol Design Characteristics. *Therapeutic Innovation and Regulatory Science*, **2019**, 2168479019867284	1.2	5
33	Research methodology and practical issues relating to the conduct of a medical device registry. **2019**, 16, 490-501		7
32	How to Document a Clinical Study and Avoid Common Mistakes in Study Conduct?. **2019**, 121-132		
31	Increasing complexity in oncology phase I clinical trials. **2019**, 37, 519-523		6
30	Smart Home-based IoT for Real-time and Secure Remote Health Monitoring of Triage and Priority System using Body Sensors: Multi-driven Systematic Review. **2019**, 43, 42		83
29	A rapid method for post-antibiotic bacterial susceptibility testing. **2019**, 14, e0210534		14
28	Key indicators of phase transition for clinical trials through machine learning. **2020**, 25, 414-421		11
27	Continued investigator engagement: Reasons principal investigators conduct multiple FDA-regulated drug trials. **2020**, 17, 100502		3
26	Point-of-Care Clinical Trials in Sports Medicine Research: Identifying Effective Treatment Interventions Through Comparative Effectiveness Research. **2020**, 55, 217-228		5
25	An interactive retrieval system for clinical trial studies with context-dependent protocol elements. **2020**, 15, e0238290		
24	21 Code of Federal Regulations Part 11-Compliant Digital Signature Solution for Cancer Clinical Trials: A Single-Institution Feasibility Study. **2020**, 4, 854-864		0
23	Using systematic data categorisation to quantify the types of data collected in clinical trials: the DataCat project. **2020**, 21, 535		3

22	8. Klinische Studien zwischen GCP, CRO und Behörden. **2020**, 257-272		
21	Assessing Patient Participation Burden Based on Protocol Design Characteristics. *Therapeutic Innovation and Regulatory Science*, **2020**, 54, 598-604	1.2	1
20	Best practices for streamlining development. **2021**, 5-10		
19	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group. **2021**, 27, 2416-2423		7
18	Leveraging Informatics and Technology to Support Public Health Response: Framework and Illustrations using COVID-19. **2021**, 13, e1		3
17	ACE: the Advanced Cohort Engine for searching longitudinal patient records. **2021**, 28, 1468-1479		2
16	Clinical Study Conduct and Monitoring. **2011**, 423-469		
15	Statistical Approaches to Improving Trial Efficiency and Conduct. **2014**, 71-84		
14	Predictive Analytics to Support Clinical Trials Get Healthier. **2018**, 222-239		
13	Le crowdfunding au secours de l'industrie des biotechnologies santé. **2018**, 44, 135-157		
12	CLIPS: An interactive retrieval system for clinical trial studies with context-dependent protocol elements (Preprint).		
11	Recruitment and retention of the participants in clinical trials: Challenges and solutions. *Perspectives in Clinical Research*, **2020**, 11, 64-69	1.4	7
10	Protocol Development Program: A Novel Approach to Overcoming Barriers to Clinical Research. **2013**, 27, 54-61		2
9	CNS sites cooperate to detect duplicate subjects with a clinical trial subject registry. *Innovations in Clinical Neuroscience*, **2013**, 10, 17-21	1	13
8	Protocol Design Variables Highly Correlated with, and Predictive of, Clinical Trial Performance.. *Therapeutic Innovation and Regulatory Science*, **2022**, 56, 333	1.2	0
7	Defining clinical trial quality from the perspective of resource-limited settings: A qualitative study based on interviews with investigators, sponsors, and monitors conducting clinical trials in sub-Saharan Africa.. *PLoS Neglected Tropical Diseases*, **2022**, 16, e0010121	4.8	0
6	Machine Learning Prediction of Clinical Trial Operational Efficiency.. *AAPS Journal*, **2022**, 24, 57	3.7	0
5	Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion.. *Npj Digital Medicine*, **2022**, 5, 58	15.7	1

4	A good use of time? Providing evidence for how effort is invested in primary and secondary outcome data collection in trials.	
3	A good use of time? Providing evidence for how effort is invested in primary and secondary outcome data collection in trials. **2022**, 23,	0
2	Adaptive clinical trials in public health emergency contexts: ethics considerations. 8, 130	0
1	Assessment of the Relationship Between Protocol Adherence, Study Complexity and Personnel in Surgical Clinical Trials.	0